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Abstract
Background: Major shoulder surgery often results in severe post-operative pain and a variety of interventions
have been developed in an attempt to address this. The continuous slow infusion of a local anaesthetic directly
into the operative site has recently gained popularity but it is expensive and as yet there is little conclusive
evidence that it provides additional benefits over other methods of post-operative pain management.
Methods/Design: This will be a randomised, placebo-controlled trial involving 158 participants. Following
diagnostic arthroscopy, all participants will undergo arthroscopic subacromial decompression with or without
rotator cuff repair, all operations performed by a single surgeon. Participants, the surgeon, nurses caring for the
patients and outcome assessors will be blinded to treatment allocation. All participants will receive a pre-incision
bolus injection of 20 mls of ropivacaine 1% into the shoulder and an intra-operative intravenous bolus of
parecoxib 40 mg. Using concealed allocation participants will be randomly assigned to active treatment (local
anaesthetic ropivacaine 0.75%) or placebo (normal saline) administered continuously into the subacromial space
by an elastomeric pump at 5 mls per hour post-operatively. Patient controlled opioid analgesia and oral analgesics
will be available for breakthrough pain. Outcome assessment will be at 15, 30 and 60 minutes, 2, 4, 8, 12, 18 and
24 hours, and 2 or 4 months for decompression or decompression plus repair respectively.
The primary end point will be average pain at rest over the first 12-hour post-operative period on a verbal
analogue pain score. Secondary end points will be average pain at rest over the second 12-hour post-operative
period, maximal pain at rest over the first and second 12-hour periods, amount of rescue medication used, length
of inpatient stay and incidence of post-operative adhesive capsulitis.
Discussion: The results of this trial will contribute to evidence-based recommendations for the effectiveness of
pain management modalities following arthroscopic rotator cuff surgery. If the local anaesthetic pain-buster
provides no additional benefits over placebo then valuable resources can be put to better use in other ways.
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Background
Surgical options for rotator cuff disease that has failed to
improve with conservative treatments include open or
arthroscopic subacromial decompression (ASD) [1] with
or without rotator cuff repair (RCR) [2]. Arthroscopic
approaches are being increasingly used because of pur-
ported advantages including earlier recovery, hypothe-
sised to be due to preservation of the deltoid muscle with
this approach; smaller scars; and the ability to access the
glenohumeral joint to exclude other causes of shoulder
pain. We recently completed a Cochrane systematic
review of randomised controlled trials to determine the
effectiveness and safety of surgery for rotator cuff disease
[3]. We identified six trials that had compared arthro-
scopic to open subacromial decompression and while it
was not possible to draw firm conclusions due to their
overall poor quality, none of the trials reported significant
differences between trial arms in terms of comparative
improvements in pain, function or participant evaluation
of success, while four trials reported earlier recovery with
arthroscopic decompression. There were also no differ-
ences between trial arms for adverse events including
post-operative adhesive capsulitis (or stiff painful shoul-
der or frozen shoulder).
Post-operative pain is often a problem following major
shoulder surgery and may delay mobilisation of the
shoulder [4]. It has been postulated that this contributes
to the relatively high reported rates of post-operative
adhesive capsulitis (10%) [1]. Optimal management of
post-operative pain may therefore also be important in
aiding early rehabilitation and reducing the incidence of
post-operative adhesive capsulitis.
A variety of strategies may be used to manage post-opera-
tive pain including low dose continuous intravenous opi-
oids with or without patient managed bolus doses using
patient controlled analgesia (PCA) pumps [5], intra-artic-
ular injections of morphine or local anaesthetic [6],
regional nerve blocks [7], non-steroidal anti-inflammatory
drugs (NSAIDs) [8], and oral analgesics. While effective,
there are known disadvantages to each of these modalities.
Most PCA pump systems require expensive equipment [5]
(around AU$3,000 at the hospitals in our study), as well
as education of patients and monitoring by nursing staff.
Strong opioid analgesia may cause nausea and vomiting,
respiratory depression, sedation and constipation; neural
blockade may be complicated by pneumothorax, nerve
injury [9] and respiratory depression [10] while there are
numerous potential adverse effects of NSAID therapy
include peptic ulcer disease, platelet dysfunction, hyper-
tension, fluid retention and renal impairment [11].
Use of a pre-emptive (before incision) bolus dose of local
anaesthetic (e.g. lignocaine, bupivacaine or ropivacaine)
injected into either the glenohumeral joint and/or subac-
romial space is gaining wide acceptance as an alternative
method for pain management following shoulder surgery.
Pre-emptive analgesia is purported to induce prophylactic
neural blockade thus blocking nociceptive input and
reducing post-operative pain [12]. The effect may be
enhanced by the addition of a direct operative site infu-
sion of local anaesthetic delivered by disposable infusion
pumps. For example, elastomeric pumps provide direct
pre-set delivery of local anaesthetic to the shoulder joint
via a fine multi orifice slow infusion catheter which is eas-
ily positioned by the surgeon. The catheter is accurately
placed in the subacromial space under arthroscopic or
direct visualisation, reducing the risk of nerve, soft tissue
and vascular damage [13].
Administration of local anaesthetic has been performed
by direct infiltration, intermittent lavage, continuous
infusion with PCA bolus or PCA alone and some of the tri-
als have also included pre-emptive or intra-operative anal-
gesia and/or NSAIDS. Shoulder operations have included
open as well as arthroscopic surgery, and surgery to the
capsule and ligaments as well as to the rotator cuff. Seven
previous randomised placebo-controlled trials of differing
methodological quality have assessed the efficacy of local
anaesthetic (lignocaine, bupivacaine or ropivacaine) con-
tinuously infused into the operative site following various
types of major shoulder surgery [13-19]. While difficult to
make direct comparisons between trials because of these
differences, some trials have found that compared with
placebo, local anaesthetic resulted in lower post-operative
pain scores with or without less analgesia use, [14,15,17-
19] while other studies have found no significant differ-
ences in regard to pain and use of rescue medication
between treatment groups [13,16].
While ropivacaine is now considered the local anaesthetic
of choice despite its greater cost, earlier trials used either
the shorter acting lignocaine or bupivacaine. Bupivacaine
has been shown to cause greater dose related central nerv-
ous system and cardiac toxicity than ropivacaine [20].
Ropivacaine has less motor blockade than either of these
drugs [21], which may be clinically important in terms of
active post-operative mobilisation of the shoulder. Previ-
ous trials have also failed to take into account potential
confounding due to different operative procedures or, in
the case of multiple surgeons and/or centres, potentially
different surgical skills, technique, equipment and peri-
operative and post-operative care.
In our setting, post-operative pain management has tradi-
tionally consisted of pre-emptive local anaesthetic (ropi-
vacaine) and post-operative PCA opioids. Recently and
concurrently, both intra-operative intravenous parecoxib
a selective COX-II inhibitor, and direct operative ropi-BMC Musculoskeletal Disorders 2008, 9:56 http://www.biomedcentral.com/1471-2474/9/56
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vacaine infusion pumps were introduced as standard prac-
tice although evidence for their added benefits is limited.
The disposable pump with single or dual catheters and
ropivacaine costs $AUD300–600 and $155 respectively
(at time of publication), while a single pre-emptive bolus
of 20 mls 1% ropivacaine costs $20 and an IV bolus of
parecoxib (40 mg) costs only $25. Reported adverse
effects of infusion pumps include difficulty in removal of
the catheter, too rapid delivery of the drug, leakage with
local contamination, and breakage of the catheter tip leav-
ing a remnant in the joint [22,23]. To warrant continued
use of the ropivacaine infusion, it would need to be dem-
onstrated that its benefit/s in terms of pain relief, reduc-
tion in drug-related adverse effects, earlier shoulder
mobilisation and/or reduced hospital stay is/are worth
the additional costs.
The aim of this randomised placebo controlled trial is to
determine the efficacy and safety of a continuous infusion
of ropivacaine 0.75% (Naropin – AstraZeneca) delivered
by a single catheter 'Painbuster'(I-Flow Corporation, Lake
Forest, USA) pain management system when used follow-
ing elective arthroscopic rotator cuff surgery. Our hypoth-
esis is that continuous infusion of local anaesthetic
following rotator cuff surgery would be equivalent to pain
relief provided by a placebo in the setting of pre-emptive
ropivacaine, intra-operative parecoxib and post-operative
intravenous morphine and oral dextropropoxyphene
hydrochloride/paracetamol available on demand.
Methods
Design
This will be a randomised placebo-controlled trial (Figure
1). Participants, the single surgeon, nurses caring for the
participants and outcome assessors will all be blinded to
treatment allocation.
Setting and Participants
Participants will be recruited from the private community-
based practice of a single orthopaedic shoulder surgeon in
Melbourne, Australia. The decision to include only one
surgeon will eliminate any potential confounding of
results due to differences in surgical skill, technique and
care across treatment arms. One of two elective operations
will be performed based upon diagnostic arthroscopy at
the time of operation: ASD or ASD plus RCR. All rotator
cuff surgery will be performed at either the Mercy Private
Hospital or Linacre Private Hospital in Melbourne,
Australia.
All consecutive, eligible patients who fulfil selection crite-
ria will be offered study participation. Inclusion criteria
will be adults aged 18 years or over in whom elective sub-
acromial decompression or rotator cuff repair is planned.
Exclusion criteria will be: (i) patients with massive or
irreparable rotator cuff tears; (ii) patients requiring grafts
to fill the defect; (iii) previous injury or surgery to the
shoulder i.e. fracture or revision surgery; (iv) previous
mastectomy on the affected side; (v) peripheral neuropa-
thy affecting the upper limbs; (vi) chronic opioid use; (vii)
morbid obesity (body mass index greater than 35 kg per
metre squared); (viii) Parkinson's disease; (ix) pregnancy;
(x) contraindication to parecoxib including aspirin sensi-
tive asthma, history of recent gastric or duodenal bleed-
ing, severe renal impairment or sulphonamide allergy;
(xi) inability to understand written and/or spoken
English.
Ethics
The Monash University and Mercy Aged and Health Care
Ethics Committees have approved the study and all partic-
ipants will provide written informed consent.
Randomisation
Once eligibility has been assessed following diagnostic
arthroscopy, participants will be randomly assigned in
random permuted blocks of differing sizes to either active
Trial profile Figure 1
Trial profile
                        Pain-Buster Management Trial 
                                   FLOW CHART 
                  Included 
                 Outcomes 
Ineligible 
Failure to meet 
inclusion criteria
Meets exclusion 
criteria 
Does not wish to 
be in the study
                Outcomes 
Pain buster
    saline 
Pain buster
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Pain buster
   saline 
Pain buster 
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decompression plus rotator cuff 
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Arthroscopic subacromial         
decompression  alone 
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      Diagnostic arthroscopy 
             (Allocation) 
                  Intraoperative 
   Intravenous parecoxib (40mgs) 
       Initial screening interview 
    Pre-emptive ropivacaine   (20mls of 1%) 
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treatment (ropivacaine) or placebo (normal saline), strat-
ified by type of operation (ASD or ASD plus RCR) (Figure
1). The randomisation sequence will be generated using a
computer generated table of random numbers by the
study biostatistician. Stratified allocations will be sealed
in opaque and consecutively numbered envelopes kept in
a locked location. These will be opened in sequence by an
independent administrator not involved in the eligibility
or outcome assessment or treatment administration.
Interventions
The surgeon's standard surgical protocol for rotator cuff
surgery will be adhered to as follows: Participants will be
asked to cease all NSAIDs two weeks prior to commence-
ment of the study but will be allowed codeine, paraceta-
mol or dextropropoxyphene. All operations will be
performed under general anaesthesia using a standardised
method consisting of propofol 2–2.5 mg/kg and fentanyl
1–2 mcg/kg as induction agents, nitrous oxide/oxygen
2:1, +/- isoflurane, morphine as required to maintain
heart rate, blood pressure, respiratory rate within normal
limits, and spontaneous ventilation on a laryngeal mask
unless contra-indicated.
All patients will receive a total of 20 mls of 1% ropivacaine
injected as a pre-emptive bolus dose into both the gleno-
humeral joint and the subacromial space fifteen minutes
prior to insertion of the arthroscope. During the operation
all patients will receive an intravenous bolus of 40 mg of
parecoxib. At the conclusion of the surgery, all patients
will have insertion of a 'Pain buster' catheter into the sub-
acromial space with the position verified by direct or
arthroscopic vision. According to blinded randomised
treatment allocation the 'Pain buster' elastomeric pump
will contain 180 mls of either 0.75% ropivacaine or an
identical placebo of normal saline administered at 5 mls
per hour.
All patients will have access to alternative analgesia for
break through pain including both a PCA pump of intra-
venous morphine available on demand with a lock out
period and dextropropoxyphene hydrochloride/paraceta-
mol. All medications will be recorded.
Outcome assessment
All assessors collecting and assessing outcome will be
blinded to treatment allocation. One assessor will per-
form all baseline, and 2 or 4 month (JC) assessments. Post
operative assessment of pain, analgesia and duration of
hospital stay will be recorded by nursing staff.
Baseline data will include gender, age at operation, domi-
nance, side of operation, height, weight, history of diabe-
tes, employment, duration of symptoms and
compensation status. As a verbal analogue pain scale
(VAPS) will be used to measure pain postoperatively, par-
ticipants will be taught to use the scale at the time of pre-
operative baseline assessment to measure current level of
pain at rest. The VAPS is an 11-point scale where 0 = no
pain and 10 = worst pain imaginable.
Outcomes will be assessed post operatively at 15, 30 and
60 minutes, 2, 4, 8, 12, 18 and 24 hours, and 2 or 4
months for ASD or ASD and RCR respectively. Average
pain at rest and maximal pain over the first and second 12
hour post-operative periods, will be computed using the
VAPS. The amount of rescue medication used over the first
and second 12 hour post-operative periods will be com-
puted as intravenous opioid intake in mgs and oral anal-
gesic intake as a tablet count.
Range of movement of the shoulder will be measured at
baseline and at 2 or 4 months for ASD or ASD plus RCR
respectively. Active shoulder movements will be meas-
ured according to a standardised and reliable protocol
[24]: Total shoulder flexion (TSF), total shoulder abduc-
tion (TSA) and external rotation in neutral (ERN) will be
measured with a gravity inclinometer (in degrees) and
internal rotation will be assessed by measuring distance
(in centimetres) from the base of the occiput to how high
the hand will reach up behind the back (HBB). Post-oper-
ative adhesive capsulitis will be defined as having symp-
toms of shoulder pain and stiffness and restriction of
movement of at least 30° in two or more planes at 2 or 4
months post-operatively for ASD or ASD plus RCR
respectively.
Length of hospital stay will be measured in days from time
of surgery and all adverse effects will be recorded.
The primary end point will be the average pain at rest over
the first 12 hour post-operative period. Secondary end
points will be the average pain at rest over the second 12-
hour post-operative period, the maximal pain over the
first and second 12-hour periods, the amount of rescue
medication used, late discharge (>1 bed day) from hospi-
tal following ASD, early or late discharge (< or > 2 bed
days) following ASD plus RCR, and the incidence of post-
operative adhesive capsulitis up to 2 or 4 months follow-
ing ASD or ASD plus RCR respectively.
Sample Size
Sample size is based upon clinical equivalence being
deemed as a difference in mean pain scores of +/-1 point
on a 10 point scale. That is, any difference between groups
of 1 point or less will be regarded as equivalent for practi-
cal purposes. Statistically, equivalence will be declared if
the 90% CI for the difference in mean pain scores between
the groups lies entirely within the interval -1 to +1. To
have 80% probability that this equivalence will occurBMC Musculoskeletal Disorders 2008, 9:56 http://www.biomedcentral.com/1471-2474/9/56
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when the two infusion therapies are actually exactly
equivalent requires 70 patients per arm, assuming a stand-
ard deviation of 2 points within each arm (obtained from
pilot work). This sample size will also be able to detect a
difference of 0.95 points with 80% power and a two-sided
5% significance level. Allowing for 10% dropout, the sam-
ple size is inflated to 78 patients per group.
Data Analysis
The principal analyses will involve the comparison of
average scores of pain at rest in the first 12 hours post-
operation between the ropivacaine pump infusion and
placebo patients using an intention-to-treat analysis. This
will be performed by multiple regression adjusting for
infusion type and type of operation. Similar analyses will
compare maximal pain at rest in the first 12 hours and
average and maximal pain at rest in the second 12-hour
post-operative period. Sensitivity analyses to assess
dependence upon potential baseline imbalance in prog-
nostic factors will also be performed. Other secondary
outcome analyses will include amount of morphine
administered, the incidence of complications, late dis-
charge from hospital (>1 bed day) following ASD, early or
late discharge (< or > 2 bed days) following RCR, and the
incidence of post-operative adhesive capsulitis up to 2 or
4 months following ASD or ASD plus RCR respectively.
Further analyses will assess differences between arms in
maximum and average pain scores at rest adjusted for
amount of opioid used.
Discussion
The results of this trial will contribute to evidence-based
recommendations for the effectiveness of pain manage-
ment modalities following arthroscopic rotator cuff sur-
gery. If we can show that the pain-buster is equivalent to
current treatment and adds nothing to current pain man-
agement then this will reduce the costs of the surgical pro-
cedure and hospitalisation. Strengths of our trial include
blinding of all personnel involved in participant care
including the surgeon; assurance of homogeneity of study
population by pre-randomisation identification of the
surgical procedure required; use of a realistic placebo infu-
sion; use of a single surgeon and single post operative
regime limiting confounding; and statistical power to
detect small differences of importance.
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